Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 7/2013

01-09-2013 | Original Paper

High Uptake of HIV Testing in a Cohort of Male Injection Drug Users in Delhi, India: Prevalence and Correlates of HIV Infection

Authors: Avina Sarna, Waimar Tun, Vartika Sharma, Mary Sebastian, Ira Madan, Amita Yadav, Meredith Sheehy, Dean Lewis, Ibou Thior

Published in: AIDS and Behavior | Issue 7/2013

Login to get access

Abstract

We report baseline findings from a longitudinal cohort study to examine HIV incidence, high-risk injection and sexual behaviors of 3,792 male injection drug users (IDUs) in Delhi. The majority (95.4 %) accepted HIV testing; HIV prevalence was 21.9 %. In multivariate analysis, belonging to states adjacent to Delhi (AOR: 1.23; 95 % CI: 1.07–1.52), earning INR 500–1,500 (AOR: 2.38; 95 % CI: 1.43–3.96); duration of drug use 2–5 years (AOR: 2.02; 95 % CI: 1.09–3.73), 6–10 years (AOR: 2.81; 95 % CI: 1.55–5.11), ≥11 years (AOR: 3.35; 95 % CI: 1.84–6.11); prior HIV testing (AOR: 1.60; 95 % CI: 1.35–1.91), self-reported risky-injection behavior (AOR: 1.60; 95 % CI: 1.33–1.92), and utilization of harm-reduction services (AOR: 1.32; 95 % CI: 1.11–1.58) were positively associated with HIV infection. Alcohol use ≤2 times/week (AOR: 0.67; 95 % CI: 0.55–0.82) or ≥3 times/week (AOR: 0.74; 95 % CI: 0.54–1.01), unit increase in age (AOR: 0.99; 95 % CI: 0.98–1.00), ≥7 years of schooling (AOR: 0.82; 95 % CI: 0.66–1.02) and unsafe sex with any female partner (AOR: 0.69; 95 % CI: 0.55–0.86) were negatively associated with HIV infection. HIV prevalence remains high among male IDUs in Delhi. HIV prevention programs should include comprehensive package of services for IDUs.
Literature
1.
NACO. Annual Report. Department of AIDS Control, Ministry of Health and Family Welfare, 2009–2010.
2.
3.
Sarna A, Tun W, Bhattacharya A, Lewis D, Singh Y, Apicella L. Assessment of unsafe injection practices and sexual risk behaviors among male injecting drug users in two urban cities of India using respondent driven sampling. Southeast Asian J Trop Med Hyg. 2012;43(3):652–67.
4.
Mahanta J, Medhi G, Paranjpe R, Roy N, Kohli A, Akojiam B, et al. Injecting and sexual risk behaviours, sexually transmitted infections and HIV prevalence in injecting drug users in three states in India. AIDS. 2008;22(Supplement 5):S59–68.PubMedCrossRef
5.
Panda S, Kumar M, Lokabiraman S, Jayashree K, Satagopan M, Solomon S, et al. Risk factors for HIV infection in injection drug users and evidence for onward transmission of HIV to their sexual partners in Chennai, India. J Acquir Immune Defic Syndr. 2005;39(1):9–15.PubMedCrossRef
6.
Panda S, Chatterjee A, Bhattacharya SK, Manna B, Singh PN, Sarkar S, et al. Transmission of HIV from injecting drug users to their wives in India. Int J STD AIDS. 2000;11:468–73.PubMedCrossRef
7.
Uusküla A, McMahon MJ, Kals M, Talu A, Abel-Ollo K, Rüütel K, Jarlais DC. Risk for heterosexual HIV transmission among non-injecting female partners of injection drug users in Estonia. AIDS Behav. 2011. doi:10.​1007/​s10461-011-0078-9.
8.
Latkin C, Srikrishnan A, Yang C, Johnson S, Solomon S, Kumar S, et al. The relationship between drug use stigma and HIV injection risk behaviors among injection drug users in Chennai, India. Drug Alcohol Depend. 2010;110(3):221–7.PubMedCrossRef
9.
NACO. National Behaviour Surveillance Survey. Delhi: National AIDS Control Organisation, Ministry of Health and Family Welfare, Government of India, 2006.
10.
Solomon S, Srikrishnan A, Celentano D, Johnson S, Vasudevan C, Murugavel K, et al. The intersection between sex and drugs: a cross-sectional study among the spouses of injection drug users in Chennai, India. BMC Public Health. 2011;11(39):10.
11.
Des Jarlais DC, Perlis T, Poznyak V. Characteristics of injecting drug users (IDUs) in different regions of the world: WHO Phase II Study. Paper presented at the international conference on the reduction of drug related harm, Melbourne;2004.
12.
Des Jarlais DC, Semaan S. Interventions to reduce the sexual risk behaviour of injecting drug users. Int J Drug Policy. 2005;16S:S58–66.CrossRef
13.
Desenclos JC, Papaevangelou G, Ancelle-Park R. Knowledge of HIV serostatus and preventive behaviour among European injecting drug users. The European Community Study Group on HIV in Injecting Drug Users. AIDS. 1993;7(10):1371–7.PubMedCrossRef
14.
Vanichseni S, Choopanya K, Des Jarlais DC, Plangsringarm K, Sonchai W, Carballo M, et al. HIV testing and sexual behavior among intravenous drug users in Bangkok, Thailand. J Acquir Immune Defic Syndr. 1992;5(11):1119–23.PubMed
15.
Grau LE, White E, Niccolai LM, Toussova OV, Verevochkin SV, Kozlov AP, Heimer R. HIV disclosure, condom use, and awareness of HIV infection among HIV-positive, heterosexual drug injectors in St. Petersburg, Russian Federation. AIDS Behav. 2011;15(1):45–7.PubMedCrossRef
16.
17.
Baveja B, Chattopadhya D, Khera R, Joshi P. A cross sectional serological study of the co-infection of hepatitis B virus, hepatitis C virus and human immunodeficiency virus amongst a cohort of IDUs at Delhi. Indian J Med Microbiol. 2003;21(4):280–3.PubMed
18.
Solomon SS, Celentano DD, Srikrishnan AK, Vasudevan CK, Murugavel KG, Iqbal SH, Anand S, Kumar MS, Latkin C, Solomon S, Mehta SH. Low incidences of human immunodeficiency virus and hepatitis C virus infection and declining risk behaviors in a cohort of injection drug users in Chennai, India. Am J Epidemiol. 2010;172(11):1259–67.PubMedCrossRef
19.
Solomon SS, Srikrishnan AK, Mehta SH, Vasudevan CK, Murugavel KG, Thamburaj E, Anand S, Kumar MS, Latkin C, Solomon S, Celentano DD. High prevalence of HIV, HIV/hepatitis C virus co-infection and risk behaviors among IDUs in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr. 2008;49(3):327–32.PubMedCrossRef
20.
21.
Behrens T, Taeger D, Wellmann J, Keil U. Different methods to calculate effect estimates in cross-sectional studies. A comparison between prevalence odds ratios and prevalence ratio. Methods Inf Med. 2004;43(5):505–9.PubMed
22.
Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702–6.PubMedCrossRef
23.
Cook T. Advanced statistics: up with odds ratios! A case for odds ratios when outcomes are common. Acad Emerg Med. 2002;9:1430–4.PubMedCrossRef
24.
Eicher A, Crofts N, Benjamin S, Deutschmann P, Rodger A. A certain fate: spread of HIV among young injecting drug users in Manipur, North-East India. AIDS CARE. 2000;12(4):497–504.PubMedCrossRef
25.
Buxton M, Vlahov D, Strathdee S, Jarlais DD, Morse E, Ouellet L, et al. Association between injection practices and duration of injection among recently initiated injection drug users. Drug Alcohol Depend. 2004;75(2):177–83.CrossRef
26.
Fennema J, Ameijden EV, Hoek AVD, Coutinho R. Young and recent-onset injecting drug users are at higher risk for HIV. Addiction. 1997;92:1457–65.PubMedCrossRef
27.
Razak MH, Jittiwutikarn J, Suriyanon V, Vongchak T, Srirak N, Beyrer C, et al. HIV prevalence and risks among injection and noninjection drug users in northern Thailand: need for comprehensive HIV prevention programs. J Acquir Immune Defic Syndr. 2003;33(2):259–66.PubMedCrossRef
28.
Vanichseni S, Kityaporn T, Maestro T. Continued high HIV-1 incidence in a vaccine preparatory trial cohort of injection drug users in Bangkok, Thailand. AIDS. 2001;15:397–405.PubMedCrossRef
29.
Corneil T, Kuyper L, Shoveller J, Hogg R, Li K, Spittal P, et al. Unstable housing, associated risk behaviour and increased risk for HIV infection among injection drug users. Health Place. 2006;12:78–85.CrossRef
30.
Jarlais DD, Braine N, Friedmann P. Unstable housing as a factor for increased injection risk behavior at US syringe exchange programs. AIDS Behav. 2007;1(6 Supplement):78–94.CrossRef
31.
Oetting ER, Beauvais F. Peer cluster theory: drugs and the adolescent. J Couns Dev. 1986;65(1):17–22.CrossRef
32.
Wattana W, van Griensven F, Rhucharoenpornpanich O, et al. Respondent driven sampling to assess characteristics and estimate the number of injection drug users in Bangkok, Thailand. Drug Alcohol Depend. 2007;90:228–33.PubMedCrossRef
33.
34.
Samuels J, Vlahov D, Anthony J, Chaisson R. Measurement of HIV risk behaviors among intravenous drug users. Br J Addict. 1992;87(3):417–28.PubMedCrossRef
35.
Block J, Block JH, Keyes S. Longitudinally foretelling drug usage in adolescence: early childhood personality and environmental precursors. Child Dev. 1988;59(2):336–55.PubMedCrossRef
36.
Salganik M, Heckathorn D. Sampling and estimation in hidden populations using respondent-driven sampling. Soc Methodol. 2004;34:193–239.CrossRef
37.
Magnani R, Sabin K, Saidel T, Heckathorn D. Review of sampling hard-to-reach and hidden population for HIV surveillance. AIDS. 2005;19(Supplement 2):S67–72.PubMedCrossRef
Metadata
Title
High Uptake of HIV Testing in a Cohort of Male Injection Drug Users in Delhi, India: Prevalence and Correlates of HIV Infection
Authors
Avina Sarna
Waimar Tun
Vartika Sharma
Mary Sebastian
Ira Madan
Amita Yadav
Meredith Sheehy
Dean Lewis
Ibou Thior
Publication date
01-09-2013
Publisher
Springer US
Published in
AIDS and Behavior / Issue 7/2013
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-013-0442-z

Other articles of this Issue 7/2013

AIDS and Behavior 7/2013 Go to the issue

Substantive Review

HIV-related Stigma as a Barrier to Achievement of Global PMTCT and Maternal Health Goals: A Review of the Evidence

Original Paper

Sexual Risk Behaviors among Club Drug Users in Shanghai, China: Prevalence and Correlates

Original Paper

Maternal HIV Serostatus, Mother–Daughter Sexual Risk Communication and Adolescent HIV Risk Beliefs and Intentions

Original Paper

HIV Testing and Intimate Partner Violence Among Non-Pregnant Women in 15 US States/Territories: Findings from Behavioral Risk Factor Surveillance System Survey Data

Original Paper

HIV Disease Burden and Related Risk Behaviours Among Men Who Have Sex with Men in Yuxi Prefecture, Yunnan Province, China: 2010−2011

Original Paper

Sexual Risk Behavior Associated with Transition to Injection Among Young Non-Injecting Heroin Users
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits